Market Exclusive

Analyst Activity – Wedbush Reiterates Outperform on Fate Therapeutics (NASDAQ:FATE)

Analyst Ratings For Fate Therapeutics (NASDAQ:FATE)

Today, Wedbush reiterated its Outperform rating on Fate Therapeutics (NASDAQ:FATE) with a price target of $10.00.

Some recent analyst ratings include

Recent Insider Trading Activity For Fate Therapeutics (NASDAQ:FATE)
Fate Therapeutics (NASDAQ:FATE) has insider ownership of 10.88% and institutional ownership of 68.75%.

Recent Trading Activity for Fate Therapeutics (NASDAQ:FATE)
Shares of Fate Therapeutics closed the previous trading session at with shares trading hands.

Exit mobile version